The estimated Net Worth of Edmund Harrigan is at least $14.2 Million dollars as of 29 May 2024. Edmund Harrigan owns over 6,652 units of Karuna Therapeutics Inc stock worth over $8,461,459 and over the last 9 years he sold KRTX stock worth over $4,520,900. In addition, he makes $1,264,680 as Independent Director at Karuna Therapeutics Inc.
Sign up
Edmund Harrigan KRTX stock SEC Form 4 insiders trading
Edmund has made over 8 trades of the Karuna Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 6,652 units of KRTX stock worth $2,194,029 on 29 May 2024.
The largest trade he's ever made was selling 30,000 units of Karuna Therapeutics Inc stock on 12 June 2020 worth over $2,753,700. On average, Edmund trades about 1,611 units every 54 days since 2015. As of 29 May 2024 he still owns at least 25,654 units of Karuna Therapeutics Inc stock.
You can see the complete history of Edmund Harrigan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Edmund Harrigan biography
Dr. Edmund P. Harrigan M.D. serves as Independent Director of the Company. Dr. Harrigan served in a variety of roles at Pfizer Inc. from March 2003 to July 2015, most recently serving as Senior Vice President of Worldwide Safety and Regulatory. Dr. Harrigan’s previous executive leadership roles at Pfizer included serving as Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Before entering the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years. He currently serves on the board of directors of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD), Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) and Incyte Corporation (NASDAQ: INCY). Dr. Harrigan earned his B.A. degree in Chemistry from St. Anselm College and holds an M.D. from the University of Massachusetts at Worcester. Our board of directors believes that Dr. Harrigan is qualified to serve on our board of directors due to his scientific and business experience in the pharmaceutical and healthcare industries.
What is the salary of Edmund Harrigan?
As the Independent Director of Karuna Therapeutics Inc, the total compensation of Edmund Harrigan at Karuna Therapeutics Inc is $1,264,680. There are 2 executives at Karuna Therapeutics Inc getting paid more, with Steven Paul having the highest compensation of $10,050,700.
How old is Edmund Harrigan?
Edmund Harrigan is 67, he's been the Independent Director of Karuna Therapeutics Inc since 2011. There are 1 older and 12 younger executives at Karuna Therapeutics Inc. The oldest executive at Karuna Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the CEO, Pres & Chairman.
What's Edmund Harrigan's mailing address?
Edmund's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.
Insiders trading at Karuna Therapeutics Inc
Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over $496,938,545 worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth $53,814,390 . The most active insiders traders include Health Llc Pure Tech, James Healy, and Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $18,341,187. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth $636,600.
What does Karuna Therapeutics Inc do?
we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
What does Karuna Therapeutics Inc's logo look like?
Complete history of Edmund Harrigan stock trades at Acadia Pharmaceuticals Inc, Bellicum Pharmaceuticals Inc, Incyte, Karuna Therapeutics Inc, and PhaseBio Pharmaceuticals
Karuna Therapeutics Inc executives and stock owners
Karuna Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Steven Paul,
Chairman of the Board, President, Chief Executive Officer -
Andrew Miller,
Chief Operating Officer -
Edmund Harrigan,
Independent Director -
Troy Ignelzi,
Chief Financial Officer -
Dr. Steven M. Paul M.D.,
CEO, Pres & Chairman -
Dr. Andrew Craig Miller,
Co-Founder & COO -
Dr. Stephen K. Brannan,
Chief Medical Officer -
Dr. Troy A. Ignelzi,
CFO & Sec. -
Stephen Brannan,
Chief Medical Officer -
Atul Pande,
Independent Director -
James Healy,
Independent Director -
Jeffrey Jonas,
Director -
Heather Preston,
Independent Director -
Robert Nelsen,
Independent Director -
Christopher Coughlin,
Independent Director -
Laurie Olson,
Director -
Giorgio Attardo,
Vice President, CMC and Preclinical Development -
Dr. Ronald N. Marcus M.D.,
Sr. VP of Medical -
Charmaine Lykins,
Chief Commercial Officer -
Dr. James E. Audia Ph.D.,
Head of Medicinal Chemistry & Sr. Adviser -
Dr. Alan Breier,
Chair of Scientific Advisory Board & Chief Clinical Advisor -
Stephanie Moore,
VP of HR -
Sharon Sawchak R.N.,
VP of Clinical Operations & Compliance -
Mia Kelley J.D.,
VP of Legal Affairs -
Jason Parker Brown,
VP of Corp. Fin. -
Venture Partners Ix, Llcarc...,
-
William Meury,
President and CEO -
Bharat M Chowrira,
Director -
Venture Partners Ix, Llcarc...,
-
Charmaine Lykins,
Chief Commercial Officer -
Health Llc Pure Tech,
-
David E. Wheadon,
-
Denice Torres,
-
William P Jr Kane,
Chief Commercial Officer -
Jason Parker Brown,
Chief Financial Officer